First Patient Dosed in Monalizumab Phase 3 Clinical Trial Triggers $50M Payment From AstraZeneca
The Pharma Data
OCTOBER 22, 2020
months (Vermorken et al, JCO 2007). Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. The activity of cetuximab as a single agent in recurrent and/or metastatic SCCHN is limited, with a 12.6%
Let's personalize your content